Urinary Level of Prostaglandin E2 Metabolite and Risk of Incident Breast Cancer
Abstract
This ongoing case-cohort analysis examines how urinary levels of prostaglandin E2 (PGE2) metabolite interacts with estrogen biosynthesis and influences breast cancer risk in postmenopausal women. The study includes 301 breast cancer cases and 308, a subsample of the cohort, who were aged 50 years or older, were postmenopausal and did not report current use of hormones. This case-cohort set mostly comprises white women with mean (standard deviation [SD]) age of 61.4 years (6.0). Approximately 70% of women underwent menopause naturally, and mean age at menopause was older in women reporting a natural menopause compared to those reporting a surgical menopause (50.8 years [SD=4.5] vs. 42.8 years [SD=8.0]). Prevalence of overweight and obesity was 66%. Few were current smokers (8%). About 60% of women reported ever use of nonsteroidal anti-inflammatory drugs (NSAIDs), with median pill-years of 24.5 (interquartile range: 7.5-55.1) among ever users. Approximately 40% of women also reported taking NSAIDs within 24 hours of urine collection; 75% of these women were chronic users of NSAIDs who reported at least 5 years of NSAID use. Urinary levels of PGE-M are being measured using liquid chromatography/tandem mass spectrometry (LC/MS/MS), which is generally accepted as the most accurate index of endogenous PGE2 formation. A recently-developed high-performance liquid chromatography/mass spectrometry method is being used to determine concentrations of 15 estrogens/estrogen metabolites with creatinine correction for urine dilution. It is expected that the present study will contribute to understanding the role of inflammation in estrogen biosynthesis and breast cancer risk in postmenopausal women.
Document Details
- Document Type
- Technical Report
- Publication Date
- Feb 01, 2011
- Accession Number
- ADA543106
Entities
People
- Sangmi Kim
Organizations
- National Institute of Environmental Health Sciences